Closing
Do PCSK9 inhibitors improve cardiac & vascular function versus placebo?
Mostly studied in coronary & atherosclerotic disease.
Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →
Where the evidence stands
A coin flip. So far, the results disagree.
NoUnsureYes
- Belief
- 0.47 (range 0.00–0.55)
- Trials for
- 1
- Trials against
- 1
- Inconclusive
- 0
Already under way
- A Phase Ⅱa Clinical Study to Evaluate the Efficacy and Safety of YN001 in Patients With Coronary Atherosclerosis in AustraliaNCT06700720 · recruiting · started 2026
- PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in Acute Coronary Syndromes (REPRESS): Study Protocol for a Multicenter Randomized…NCT06791031 · not yet recruiting · started 2026
- A Single-center, Randomized Controlled Comparison of Effect of Evolocumab Versus Standard Lipid Lowering Therapy on Plaque Progression in Patients With Acute…NCT07612774 · recruiting · started 2026
- Assessing Coronary Non-Culprit Plaque Early with Start of PCSK9 Inhibitors in Acute Myocardial InfarctionNCT06854523 · not yet recruiting · started 2025
- Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in RussiaNCT06858332 · recruiting · started 2025
The evidence so far
- Registered trials
- 46
- With posted results
- 6
- Published papers
- 1
Of 4 decided analyses: 2 favor pcsk9 inhibitors, 1 find no difference, 1 favor the comparator.
Papers
Trials
- A Randomized, Open-label, Blinded Intravascular Ultrasound Analysis, Parallel Group, Multicenter Study to Evaluate the Effect of Praluent® (Alirocumab) on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia Not Adequately Controlled With StatinNCT02984982 · 3 posted results
- High-Resolution Assessment of Coronary Plaques in a Global Evolocumab Randomized Study (HUYGENS)NCT03570697 · 3 posted results
- PCSK9 Inhibition in Patients With Symptomatic Intracranial AtherosclerosisNCT03507374
- Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and CancerNCT05976893
- Effect of Impact of PCSK9 Inhibitors on Coronary Microvascular Dysfunction in Patients With Atherosclerotic Cardiovascular Disease Proved by Myocardial Ischemia and Needing Coronarography : a Monocentric, Prospective, Randomized and Open-label Phase II TrialNCT04338165
- Trial of PCSK9 Inhibition in Patients with Acute Stroke and Symptomatic Intracranial Atherosclerosis - a Prospective, Randomized, Open-label, Blinded End-point Study with High-resolution MR Vessel Wall ImagingNCT05001984
- Effect of Alirocumab on Saphenous Vein Graft Atherosclerosis: The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot TrialNCT03542110
- Further Lipid-Lowering With PCSK9 Inhibitors for Cardiovascular Outcomes in High-Risk Coronary Plaques Assessed by CT AngiographyNCT06863545